###### Strengths and limitations of this study

-   The protocol follows the established Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols (PRISMA-P) reporting guidelines. Similarly, PRISMA guidelines will be used in the preparation of the systematic review.

-   The review will involve a comprehensive search strategy and a robust screening process.

-   The quality of included articles will be independently assessed by two authors.

-   Reporting bias may occur due to the exclusion of articles published in languages other than English, articles published prior to 2002 and unpublished articles.

-   The number of reports found may be limited, and high heterogeneity may prevent a meta-analysis.

Background {#s1}
==========

The World Health Organization (WHO) estimates that new cancer cases will increase from 14.1 million in 2012 to 21.7 million in 2030.[@R1] The greatest increase will occur in low- and lower-middle-income countries (LLMICs),[@R2] where non-communicable diseases have already replaced communicable diseases as the greatest cause of morbidity and mortality.[@R3] This growth is driven by numerous factors: population growth, increasing life expectancy, greater detection and reporting, lifestyle risk factors, and infection by oncogenic viruses, such as hepatitis B and C, human papillomavirus or *Helicobacter pylori*.[@R4]

Emotional distress commonly occurs during the cancer trajectory and ranges from subclinical distress to mental illness. It is well documented that psychiatric comorbidity is associated with reduced quality of life,[@R7] as well as poorer cancer outcomes including shorter survival.[@R8] Hence, the International Federation of Psycho-oncology Societies endorses distress as the 'sixth vital sign' in cancer[@R9] and advocates for psychosocial support to be integrated into cancer care.[@R10]

The majority of studies evaluating the prevalence of psychiatric comorbidity in cancer have been conducted in upper-income countries. A study of 2141 participants in Germany found a 12-month prevalence of mental disorders of 39.4%.[@R11] Meta-analyses have estimated the pooled prevalence of comorbid mental disorders as being 32%,[@R12] comorbid mood disorders to range from 30% to 40%[@R13] and comorbid depression to range from 8% to 24%.[@R14] In China, an upper-middle-income country, albeit with significant intra-country variation, a meta-analysis found the prevalence of depression and anxiety to be 54.9% and 49.7%, respectively.[@R15] Diagnosis of mental disorders was made using clinical interviews[@R12] or self-report instruments.[@R14]

Patients with cancer in LLMICs, compared with upper-income countries, often face significant additional challenges: cultural barriers to care may exist, diagnosis is often late and treatment options can be limited and costly.[@R16] There is often poor access to pain medication and poorer survival rates.[@R4] In upper-income countries, socioeconomic factors such as low income[@R18] and low education[@R18] have been found to be associated with increased depressive symptoms among patients with cancer. It is unclear how the challenges faced by those in LLMICs impact on psychological symptoms.

Mental health interventions in people with cancer result in improved mental health and quality of life outcomes[@R20] and reduction in medical costs to the healthcare system.[@R21] Generalisability to LLMICs may be limited due to cultural, socioeconomic and health system differences. In LLMICs, cancer care itself is under-resourced and psycho-oncology services are often scarce or non-existent.[@R10] It is important for interventions to be evidence based to justify the allocation of limited resources.

Improved understanding of psychiatric comorbidity in people with cancer in LLMICs will raise awareness of the burden of disease and may inform the development of national cancer care plans. In countries where there is no national mental health programme, some mental healthcare needs may be addressed by embedding psychological care into medical care.[@R22]

The aims of this systematic review are to describe, among adults with cancer living in LLMICS:the prevalence and determinants of psychiatric comorbiditythe efficacy of mental health interventions.

Methods {#s2}
=======

The research protocol follows the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols (PRISMA-P) guidelines.[@R23]

Eligibility criteria {#s2a}
--------------------

Studies will be selected according to the following criteria:All study designs will be included, except for case reports or small case series under 20 patients.Study participants must be:adult humans (18 years or older). Studies evaluating both adults and children will be included if the data for adults is presented separately.living in LLMICs, as defined by the World Bank country income categories. Studies evaluating countries from different income categories will be included if the data for LLMICs is presented separately.people with a diagnosis of cancer.The study must report either the prevalence of psychiatric comorbidity or assess the outcomes of psychiatric interventions. Psychiatric comorbidity must be assessed by either a validated instrument or clinical interview. Validation studies will be excluded.The search will be limited to the English language and to peer-reviewed articles.The date range will be limited from March 2002 to March 2017.

Information sources and search strategy {#s2b}
---------------------------------------

We will search MEDLINE, PsycInfo, Embase and CINAHL. We will develop a literature search strategy using a combination of medical subject headings and keywords. In order to remain relevant to current practice, we intend to calculate a contemporary pooled prevalence and focus on up-to-date interventions. We will limit the search to studies published after March 2002. This reflects the time period when non-communicable disease became a health priority for LLMICs in response to the epidemiological shift from communicable to non-communicable diseases.[@R24] Additionally, it allows for the wide adoption of the Diagnostic and Statistical Manual IV and the International Statistical Classification of Diseases, Tenth Revision diagnostic systems in order to limit phenotypic heterogeneity.[@R26]

The specific search strategy will be created in consultation with an experienced Health Sciences librarian. The draft MEDLINE search strategy is included in online [appendix 1](#SP1){ref-type="supplementary-material"}. It will be adapted to the syntax and subject headings of the other databases. The reference lists of included studies will also be screened against the eligibility criteria.
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Data management and selection process {#s2c}
-------------------------------------

Literature search results will be uploaded to Endnote X8, a software program for managing references and citations. Two authors will independently screen the titles and abstracts against the inclusion criteria and create a preliminary list of articles. One author will retrieve and screen the full text of these articles. We will record the reasons for exclusion. The authors will not be blind to the authors or journal titles. The process will be documented in the PRISMA flow diagram. Disagreements will be resolved through consensus or by adjudication by a third author.

Data collection process {#s2d}
-----------------------

Using standardised forms, one author will extract the data from the included studies. The data will be cross-checked by a second author. The key outcome is the prevalence of depression. Secondary outcomes will be the prevalence of anxiety and other mental disorders. Extracted information will include: author, year of publication, country, study design, percentage women, type of cancer, time since diagnosis, measurement tools and outcomes, intervention if relevant, and determinants of psychiatric comorbidity. For treatment studies, details regarding the intervention, control group and effect of the intervention will also be extracted. We will contact corresponding authors for clarification or for missing data.

Quality assessment {#s2e}
------------------

Quality assessment for each included study will be independently undertaken by two authors using the National Institute of Health's National Heart Lung Brain Institute Quality Assessment Tools.[@R27] The tool provides guidance for evaluating the internal validity of the study and for translating this to risk of bias. Each study will be rated as being at low, medium or high risk of bias. Disagreements will be resolved by consensus or by adjudication by a third author. We will assess publication bias using a funnel plot.

Data synthesis {#s2f}
--------------

Data on the prevalence and determinants of psychiatric comorbidity and data on interventions will be synthesised in separate tables. A systematic narrative synthesis will be presented for all tables.

Meta-analysis of prevalence data will be undertaken. Study heterogeneity will be calculated using I2statistic. Provided that depression has been evaluated in at least two studies, the overall pooled prevalence will be calculated using a random effects meta-analysis. Similarly, if other individual mental disorders have been evaluated in at least two studies, the overall pooled prevalence of these will also be calculated using a random effects meta-analysis. Subgroup analyses may be made based on geographical location, method of diagnosis and risk of bias.

The study will be reported according to the PRISMA guidelines.[@R28]
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